Boc-gly-PEG3-endo-BCN
Code | Size | Price |
---|
TAR-T14726-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T14726-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Boc-gly-PEG3-endo-BCN is a PEG-based PROTAC linker and a cleavable 2-unit PEG ADC linker, utilized in the synthesis of PROTACs[1] and antibody-drug conjugates (ADCs)[2], respectively.
CAS:
2110444-63-6
Formula:
C28H47N3O8
Molecular Weight:
553.69
Purity:
0.98
SMILES:
C(OC(NCCCOCCOCCOCCCNC(CNC(OC(C)(C)C)=O)=O)=O)[C@H]1C2C1CCC#CCC2
References
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.